Overview

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Status:
NOT_YET_RECRUITING

Trial end date:
2028-07-01

Target enrollment:

Participant gender:

Summary

Immune resistance after treatment, there is no standard treatment, one of the most important and the most effective measures is immune to combination therapy。Targeted angiogenesis therapy has always been the focus of research on the treatment of NSCLC patients with progressive disease after immunotherapy. From the mechanism of action, angiogenesis and immunosuppression are interrelated processes.

Phase:

PHASE4

Details

Lead Sponsor:

The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine

Treatments:

anlotinib
tislelizumab